ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes Mellitus
Phase 3
Terminated
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 46
- Registration Number
- NCT01514838
A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects
Phase 1
Completed
- Conditions
- Pharmacokinetic of YM150Healthy Elderly Subject
- Interventions
- Drug: Placebo
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT01514825
A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects
Phase 1
Completed
- Conditions
- HealthyPharmacokinetic of Digoxin
- Interventions
- First Posted Date
- 2012-01-23
- Last Posted Date
- 2012-01-24
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01514812
A Study is to Assess Efficacy and Safety of Tacrolimus in Active Rheumatoid Arthritis Patients Who Showed Unsuccessful Response to Existing Disease Modifying Antirheumatic Drugs (DMARDs)
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2018-08-13
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 128
- Registration Number
- NCT01511003
A Study to Assess the Efficacy and Safety of ASP1941 in Combination With Metformin in Asian Diabetes Patients
Phase 3
Completed
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 171
- Registration Number
- NCT01505426
Drug Interaction Study of Isavuconazole and Cyclosporine
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01494597
- Locations
- 🇺🇸
Covance, Madison, Wisconsin, United States
A Study to Evaluate Cardiovascular Interactions Between Mirabegron and Tamsulosin
Phase 1
Completed
- Conditions
- Healthy SubjectsPharmacokineticsCardiovascular
- Interventions
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2013-12-09
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01489696
- Locations
- 🇬🇧
Covance CRU Ltd, Leeds, United Kingdom
Post Marketing Survey of Vesicare in Japan
- First Posted Date
- 2011-12-12
- Last Posted Date
- 2014-09-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 1160
- Registration Number
- NCT01489709
A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K
Phase 1
Completed
- Conditions
- Bioavailability of ASP015KPharmacokinetics of ASP015KHealthy Subjects
- Interventions
- First Posted Date
- 2011-12-06
- Last Posted Date
- 2011-12-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01486017
- Locations
- 🇺🇸
Covance, Dallas, Texas, United States
A Single Oral Dose Study to Compare the Bioavailability Between Two Different Tablet Formulations and Assess if There is a Food Effect With the New Formulation
Phase 1
Completed
- Conditions
- Pharmacokinetics of ASP015KBioavailability of ASP015KHealthy Subjects
- Interventions
- First Posted Date
- 2011-12-05
- Last Posted Date
- 2011-12-05
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 24
- Registration Number
- NCT01484964
- Locations
- 🇺🇸
PAREXEL, Glendale, California, United States
© Copyright 2025. All Rights Reserved by MedPath